View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2020	May 08, 2020
Document Information [Line Items]
Entity Registrant Name	ATOSSA THERAPEUTICS, INC.
Entity Central Index Key	0001488039
Trading Symbol	atos
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		9,208,458
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.18 par value

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 9,351,141	$ 12,581,136
Restricted cash	110,000	110,000
Prepaid expenses	1,337,120	862,344
Research and development tax rebate receivable	734,340	739,656
Other current assets	134,519	26,130
Total current assets	11,667,120	14,319,266
Furniture and equipment, net	29,734	34,350
Intangible assets, net	60,833	68,542
Right-of-use asset	37,397	50,479
Other assets	17,218	17,218
Total Assets	11,812,302	14,489,855
Current liabilities
Accounts payable	356,252	293,171
Accrued expenses	52,474	77,888
Payroll liabilities	466,383	899,420
Lease liability	29,385	39,371
Other current liabilities	3,458	12,892
Total current liabilities	907,952	1,322,742
Long term liabilities
Lease liability long term	8,013	11,108
Total Liabilities	915,965	1,333,850
Commitments and contingencies (Note 12)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized; 671 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	1	1
Additional paid-in capital - Series B convertible preferred stock	670,999	670,999
Common stock - $0.18 par value; 175,000,000 shares authorized, and 9,130,984 shares issued and outstanding, as of March 31, 2020 and December 31, 2019, respectively	1,643,565	1,643,565
Additional paid-in capital	105,600,232	104,912,480
Accumulated deficit	(97,018,460)	(94,071,040)
Total Stockholders' Equity	10,896,337	13,156,005
Total Liabilities and Stockholders' Equity	$ 11,812,302	$ 14,489,855

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	671	671
Preferred stock, outstanding (in shares)	671	671
Common stock, par value (in dollars per share)	$ 0.18	$ 0.18
Common stock, authorized (in shares)	175,000,000	175,000,000
Common stock, issued (in shares)	9,130,984	9,130,984
Common stock, outstanding (in shares)	9,130,984	9,130,984

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating expenses
Research and development	$ 938,620	$ 1,451,236
General and administrative	1,998,389	2,613,093
Total operating expenses	2,937,009	4,064,329
Operating loss	(2,937,009)	(4,064,329)
Other expense	(10,411)	(8,978)
Loss before income taxes	(2,947,420)	(4,073,307)
Income taxes
Net loss	$ (2,947,420)	$ (4,073,307)
Loss per common share - basic and diluted (in dollars per share)	$ (0.32)	$ (0.62)
Weighted average shares outstanding - basic and diluted (in shares)	9,130,984	6,565,514

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock Additional Paid-in Capital [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018	2,379		5,846,552
Balance at Dec. 31, 2018	$ 2	$ 2,378,997	$ 1,052,372	$ 82,204,902	$ (76,831,263)	$ 8,805,010
Issuance of common stock upon warrant exercise (in shares)			2,799,188			2,800,000
Issuance of common stock upon warrant exercise			$ 503,854	10,832,856		$ 11,336,710
Conversion of convertible preferred stock to common stock (in shares)	1,677		(476,431)
Conversion of convertible preferred stock to common stock	$ 1	1,676,998	$ (85,753)	(1,591,246)
Conversion of convertible preferred stock to common stock	(1)	(1,676,998)	85,753	1,591,246
Compensation cost for stock options granted				275,833		275,833
Reclassification of stock-based compensation liability upon option cancellation				3,151,944		3,151,944
Net loss					(4,073,307)	(4,073,307)
Balance (in shares) at Mar. 31, 2019	702		9,122,171
Balance at Mar. 31, 2019	$ 1	701,999	$ 1,641,979	98,056,781	(80,904,570)	19,496,190
Balance (in shares) at Dec. 31, 2019	671		9,130,984
Balance at Dec. 31, 2019	$ 1	670,999	$ 1,643,565	104,912,480	(94,071,040)	13,156,005
Compensation cost for stock options granted				687,752		687,752
Net loss					(2,947,420)	(2,947,420)
Balance (in shares) at Mar. 31, 2020	671		9,130,984
Balance at Mar. 31, 2020	$ 1	$ 670,999	$ 1,643,565	$ 105,600,232	$ (97,018,460)	$ 10,896,337

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	1 Months Ended	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		$ (2,947,420)	$ (4,073,307)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted		687,752	275,833
Depreciation and amortization		12,326	13,983
Change in fair value of stock-based compensation liability			1,741,919
Changes in operating assets and liabilities:
Prepaid expenses		(474,776)	(325,635)
Research and development tax rebate receivable		5,316	280,242
Other assets		(108,389)	2,985
Accounts payable		63,081	110,642
Accrued expenses		(25,414)	(102,230)
Payroll liabilities		(433,037)	(43,312)
Other current liabilities		(9,434)	(30,076)
Net cash used in operating activities		(3,229,995)	(2,148,956)
CASH FLOWS FROM INVESTING ACTIVITY
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITY
Proceeds from exercise of warrants	$ 11,300,000	0	11,336,710
Net cash provided by financing activities			11,336,710
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH		(3,229,995)	9,187,754
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE		12,691,136	10,490,493
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	19,678,247	9,461,141	19,678,247
SUPPLEMENTAL DISCLOSURES
Cash and cash equivalents	19,568,247	9,351,141	19,568,247
Restricted cash	110,000	110,000	110,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	$ 19,678,247	9,461,141	19,678,247
NONCASH INVESTING AND FINANCING ACTIVITIES
Reclassification of stock-based liability awards to equity upon cancellation			$ 3,151,944

Note 1 - Nature of Operations	3 Months Ended
Note 1 - Nature of Operations	Mar. 31, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1: NATURE OF OPERATIONS On January 6, 2020, we changed our corporate name from Atossa Genetics Inc. to Atossa Therapeutics, Inc. Atossa Therapeutics, Inc. (the “Company”) was incorporated on April 30, 2009, in the State of Delaware. The Company was initially formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company’s fiscal year ends on December 31. The Company is currently focused on development of its pharmaceutical and drug delivery programs for the treatment of the Novel Coronavirus ("COVID- 19" ), breast cancer and other breast conditions. Impact of the Novel Coronavirus The continued spread of the COVID- 19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies, including causing possible disruptions in the supply of the Company’s Endoxifen, AT- H201 and the conduct of current and future clinical trials. In addition, the COVID- 19 pandemic may affect the operations of the U.S. Food and Drug Administration and other health authorities including similar entities/agencies in Sweden and Australia, which could result in delays in meetings, reviews and approvals. The evolving COVID- 19 pandemic could also directly or indirectly impact the pace of enrollment in the Company’s clinical trials for at least the next several months and possibly longer as patients may avoid or may not be able to travel to healthcare facilities and physicians’ offices except for a health emergency. Such facilities and offices may also be required to focus limited resources on non-clinical trial activities, including treatment of COVID- 19 patients, and may not be available, in whole or in part, for clinical trial activities related to Endoxifen. Additionally, while the potential economic impact brought by, and the duration of, the COVID- 19 pandemic is difficult to assess or predict, the impact of the COVID- 19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID- 19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material adverse impact on the Company’s liquidity, capital resources, operations, financial position and business and those of the third parties on which we rely. In response to the Coronavirus pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on March 27, 2020. The CARES Act, among other things, includes provisions related to refundable payroll tax credits, deferment of employer side social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act had no material impact on the Company’s income tax provision for the three months ended March 31, 2020. The Company continues to examine the elements of the CARES Act and the impact it may have on its financial position, results of operations and cash flows.

Note 2 - Going Concern	3 Months Ended
Note 2 - Going Concern	Mar. 31, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2: GOING CONCERN The Company has incurred net losses and negative operating cash flows since inception. For the three months ended March 31, 2020, the Company recorded a net loss of approximately $2.9 million and used approximately $3.2 million of cash in operating activities. As of March 31, 2020, the Company had approximately $9.4 million in cash and cash equivalents and working capital of approximately $10.8 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and is currently expending funds in research and development activities that are expected to continue to require funding. Management believes the currently available funding will only be sufficient to finance the Company’s operations for four to seven months from the date these condensed consolidated financial statements are filed with the SEC depending on the timing and extent of the Company’s clinical trials. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. As the Company is currently not generating revenues, continued timely expenditures on trials is important to bring its product(s) to market as soon as able. Management’s plans to obtain such resources for the Company include obtaining capital from the sale of its equity securities, entering into strategic partnership arrangements, potential exercise of outstanding warrants, and short-term borrowings from banks, stockholders or other related parties, if needed. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such capital will be obtained on acceptable terms. The continued spread of COVID- 19 and uncertain market conditions may limit the Company’s ability to access capital. If the Company is unable to obtain adequate capital, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned commercial activities. These conditions, in the aggregate, raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.

Note 3 - Summary of Accounting Policies	3 Months Ended
Note 3 - Summary of Accounting Policies	Mar. 31, 2020
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 3: SUMMARY OF ACCOUNTING POLICIES Basis of Presentation: The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 -Q and Rule 10 - 01 of Regulation S- X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10 -K of the Company for the year ended December 31, 2019. The year-end condensed balance sheet presented was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2020, are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Research and Development Expense: Research and development ("R&D") costs are generally expensed as incurred. R&D expenses include, for example, manufacturing expenses for our drugs under development, expenses associated with clinical trials and associated salaries and benefits. R&D expenses also include an estimated allocation of the CEO's salary and related benefits including non-cash stock-based compensation expense based on time devoted to R&D. Recently Adopted Accounting Pronouncements: On January 1, 2020, the Company adopted Accounting Standard Update ("ASU") No. 2018 - 13, Fair Value Measurement (Topic 820 ): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement , to improve the effectiveness of disclosures. The amendments remove, modify, and add certain disclosure requirements in Topic 820, “Fair Value Measurement.” The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The adoption had no impact on the Company's condensed consolidated financial statements.

Note 4 - Restricted Cash	3 Months Ended
Note 4 - Restricted Cash	Mar. 31, 2020
Notes to Financial Statements
Restricted Assets Disclosure [Text Block]	NOTE 4: RESTRICTED CASH The Company's restricted cash balance of $110,000 as of March 31, 2020 and December 31, 2019, respectively, consists entirely of cash pledged as security for the Company's issued commercial credit cards.

Note 5 - Prepaid Expenses

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Prepaid Expenses [Text Block]

NOTE

PREPAID EXPENSES

Prepaid expenses consisted of the following:

	As of March 31,		As of December 31,
	2020		2019
Prepaid research and development	$	712,387	$	507,733
Prepaid insurance		280,098		222,476
Professional services		278,298		108,850
Financial exchange fees		32,250		-
Retainer and security deposits		14,218		14,218
Prepaid rent		17,952		4,275
Other		1,917		4,792
Total prepaid expenses	$	1,337,120	$	862,344

Note 6 - Research and Development Tax Rebate Receivable	3 Months Ended
Note 6 - Research and Development Tax Rebate Receivable	Mar. 31, 2020
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 6: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE On May 23, 2017, Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform R&D activities including our Phase 1 and Phase 2 Endoxifen clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. For the three months ended March 31, 2020 and 2019, the Company recorded a rebate receivable of approximately $133,400 and $34,700, respectively. At March 31, 2020 and December 31, 2019, we had a total R&D rebate receivable of $734,340 and $739,656, respectively.

Note 7 - Payroll Liabilities

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

NOTE

PAYROLL LIABILITIES

Payroll liabilities consisted of the following:

	As of March 31,		As of December 31,
	2020		2019
Accrued bonuses	$	203,779	$	646,064
Accrued vacation		179,533		170,820
Accrued payroll		83,071		82,536
Total payroll liabilities	$	466,383	$	899,420

Note 8 - Stockholders' Equity	3 Months Ended
Note 8 - Stockholders' Equity	Mar. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8: STOCKHOLDERS’ EQUITY The Company is authorized to issue a total of 185,000,000 shares of stock consisting of 175,000,000 shares of common stock, par value $0.18 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. The Company has designated 750,000 shares of Series A junior participating preferred stock, par value $0.001 per share, 4,000 shares of Series A convertible preferred stock, par value $0.001 per share, and 25,000 shares of Series B convertible preferred stock, par value $0.001 per share, through the filings of certificates of designation with the Delaware Secretary of State. No shares of Series A junior participating preferred stock and no shares of Series A convertible preferred stock are issued and outstanding as of March 31, 2020 and December 31, 2019. Equity Distribution Agreement On February 7, 2020, Atossa Therapeutics, Inc. entered into an equity distribution agreement with Oppenheimer & Co. Inc., acting as sales agent relating to the “at-the-market” (ATM) offering and sale by Atossa of common shares, par value $0.18 per share, having an aggregate gross sales price of up to $5,000,000. Sales of the shares, if any, will be made at Atossa’s sole discretion and by means of ordinary brokers’ transactions through the facilities of the Nasdaq Capital Market at market prices, in block transactions or as otherwise agreed between Atossa and Oppenheimer. The Distribution Agreement provides that Oppenheimer will be entitled to a commission of 3.0% of the gross offering proceeds of the shares sold pursuant to the Distribution Agreement and reimbursement for certain specified expenses. Atossa has no obligation to offer or sell any shares under the Agreement, and may at any time suspend offers and sales under the Distribution Agreement. Oppenheimer & Co. Inc. may also suspend or terminate the offering of common stock being made through them upon proper notice to the Company. As of May 8, 2020, there have been 68,098 shares sold under the equity distribution agreement with net proceeds of $150,253. Warrants As of March 31, 2020, 1,070,028 warrants to purchase shares of common stock were outstanding. The warrants have an exercise price of $4.05 and expire on May 30, 2022. There were no warrant exercises during the three months ended March 31, 2020. For the three months ended March 31, 2019, the Company received approximately $11.3 million from exercises of the warrants. As a result of the warrant exercises, the Company cancelled approximately 2.8 million warrants and issued approximately 2.8 million shares of common stock. Conversion of Series B Convertible Preferred Stock There were no conversions of Series B convertible preferred stock during the three months ended March 31, 2020. During the three months ended March 31, 2019, certain holders of the Series B convertible preferred stock exercised their conversion option and converted an aggregate of 1,677 shares into 476,431 shares of the Company's common stock based on the conversion ratio of approximately 284 shares of common stock for each share of Series B convertible preferred stock.

Note 9 - Net Loss Per Share

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

NET LOSS PER SHARE

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented, they have been excluded from the calculation.

The following table summarizes the Company’s calculation of net loss per common share:

	Three Months Ended March 31,
	2020			2019
Numerator
Net loss attributable to common shareholders	$	(2,947,420	)	$	(4,073,307	)
Denominator
Weighted average common shares outstanding used to compute net loss per share, basic and diluted		9,130,984			6,565,514
Net loss per share of common stock, basic and diluted:	$	(0.32	)	$	(0.62	)

The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share, because including them would be anti-dilutive:

	Three Months Ended March 31,
	2020		2019
Options to purchase common stock		4,308,383		783,383
Series B convertible preferred stock		190,617		458,994
Warrants to purchase common stock		1,070,028		3,369,468
		5,569,028		4,611,845

Note 10 - Income Taxes	3 Months Ended
Note 10 - Income Taxes	Mar. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 10: INCOME TAXES Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of March 31, 2020 and December 31, 2019, due to the Company’s continuing operating losses.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Note 11 - Concentration of Credit Risk	3 Months Ended
Note 11 - Concentration of Credit Risk	Mar. 31, 2020
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 11: CONCENTRATION OF CREDIT RISK Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At March 31, 2020 and December 31, 2019, the Company had $8,967,650 and $12,316,429 in excess of the FDIC insured limit, respectively.

Note 12 - Commitments and Contingencies	3 Months Ended
Note 12 - Commitments and Contingencies	Mar. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 12: COMMITMENTS AND CONTINGENCIES Lease Commitments The Company evaluates all contractual agreements at inception to determine if they contain a lease. Lease liabilities are measured at present value of lease payments not yet paid, using a discounted cash flow model that requires the use of a discount rate, or incremental borrowing rate. The Company's operating lease assets consist of an office lease and a copier system lease. Our office lease expires in August of 2020 and our copier system lease expires in October of 2021. None of our leases contain options to extend. Total operating lease expense for the three months ended March 31, 2020 and 2019, was approximately $13,300 and $12,900, respectively, and variable lease payments of taxes and insurance were immaterial. As of March 31, 2020, the weighted average remaining lease term was approximately 9 months and the weighted average discount rate of our operating leases was 12%. As of March 31, 2020, the future minimum lease payments are approximately $29,500 and $12,400 for 2020 and 2021, respectively. These payments are reported in the condensed consolidated balance sheets at March 31, 2020 and 2019, net of imputed interest of approximately $4,500 and $12,900, respectively. The cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2020 and 2019, was approximately $14,700 and $14,600, respectively. Litigation and Contingencies We are subject to legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not have a material effect, individually or in the aggregate, on our financial position, results of operations or cash flows.

Note 13 - Stock Based Compensation

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

NOTE

13:

STOCK BASED COMPENSATION

Stock Option and Incentive Plan

March

24,

2020,

the Board of Directors approved the adoption of the

2020

Stock Incentive Plan (“the

2020

Plan”) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company.

awards

may

be granted under the

2020

Plan after the date that is

years from the date of stockholder approval.

September 28, 2010,

the Board of Directors approved the adoption of the

2010

Stock Option and Incentive Plan (“the

2010

Plan”) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options

may

be granted under the

2010

Plan until

September 2020.

An aggregate of

5,556

shares were initially reserved for issuance in connection with awards granted under the

2010

Plan and on

May 18, 2016,

an additional

11,111

shares were reserved for issuance under the

2010

Plan. On

May 9, 2018,

the stockholders approved an additional

125,000

shares for issuance under the

2010

Plan. On

April 12, 2018,

the stockholders approved an additional

500,000

shares for issuance under the

2010

Plan. On

May 16, 2019

the stockholders approved an additional

3,600,000

shares.

The following table presents the automatic additions to the

2010

Plan since inception pursuant to the “evergreen” terms of the

2010

Plan:

January 1,	Number of shares
2012		2,502
2013		2,871
2014		4,128
2015		5,463
2016		7,257
2017		12,623
2018		106,076
2019		233,862
2020		365,239
Total additional shares		740,021

The Company did

not

grant options to purchase shares of common stock during the

three

months ended

March 31, 2020

2019.

options were exercised during the

three

months ended

March 31, 2020

2019.

There are

676,669

shares available for grant under the

2010

Plan as of

March 31, 2020.

Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of

$687,752

and

$275,833

(excluding Liability Options discussed below) for the

three

months ended

March 31, 2020

and

2019,

respectively.

	Three Months Ended March 31,
	2020		2019
General and administrative	$	483,000	$	224,676
Research and development		204,752		51,157
Total stock compensation expense	$	687,752	$	275,833

Options issued and outstanding as of

March 31, 2020,

under the

2010

Plan and their activities during the

three

months then ended are as follows:

	Number of Underlying Shares		Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2020		4,308,383	$	3.44				-
Granted		-		-				-
Forfeited		-		-				-
Expired		-		-				-
Outstanding as of March 31, 2020		4,308,383		3.44		8.80	$	-
Exercisable as of March 31, 2020		3,832,000		3.58		8.80	$	-
Vested and expected to vest		4,308,383	$	3.44		8.80	$	-

March 31, 2020,

there were

476,383

unvested options outstanding and the related unrecognized total compensation cost associated with these options was approximately

$953,046.

This expense is expected to be recognized over a weighted-average period of

0.59

years.

Liability Options

June 27, 2018,

the Company granted

2,300,000

options to the Chief Executive Officer (CEO) and

700,000

to the Chief Financial Officer (CFO) (the "Liability Options"). Each option was exercisable for an equivalent number of shares of the Company's common stock. The Liability Options were granted pursuant to an option award agreement and were granted outside the Company’s

2010

Plan; however, they were subject to the terms and conditions of the

2010

Plan. On

January 13, 2019,

the Liability Options were canceled.

Compensation costs associated with the Liability Options were initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria were achieved for options that vest based on performance. Compensation cost was remeasured each period based on the market value of our underlying stock until award vesting or settlement.

At the time of cancellation, the fair value of Liability Options at

January 13, 2019,

was calculated using the Black-Scholes option-pricing model applying the following assumptions:

	January 13,
	2019
Risk free interest rate		2.53	%
Expected term (in years)		4.50-5.00
Stock price	$	1.36
Dividend yield		-	%
Expected volatility		121.0-123.0	%

As a result of the cancellation of these options in the

first

quarter of

2019,

the Company recognized all remaining unrecognized compensation expense related to these options of

$1,741,919,

which was included in the following captions in the condensed consolidated statements of operations:

	Period Ended March 31, 2019

General and administrative	$	1,074,183
Research and development		667,736
Total stock compensation expense	$	1,741,919

Also on

January 13, 2019,

at the same time the Liability Options were cancelled, the Company awarded a new option to the CEO to purchase

2,300,000

shares of common stock and a new option to the CFO to purchase

800,000

shares of common stock (the

“2019

Options”). The

2019

Options: (i) have an exercise price equal to the fair market value of common stock on the date of board of director approval which was

$1.36

per share, (ii) do

not

contain a net cash exercise provision, (iii) are awarded pursuant to the terms and conditions of the

2010

Plan as amended by the Board of Directors on

January 13, 2019,

to include shares issuable upon exercise of the

2019

Options and other changes to the

2010

Plan so that the

2019

Options do

not

conflict with the

2010

Plan (the “Amended Plan”), (iv) vest and are exercisable in accordance with the vesting schedule related to the

2018

Liability Options; provided, however, that the

2019

Options are

not

exercisable unless and until the Company’s stockholders approve the Amended Plan to increase the authorized number of shares available for grant under the Plan and (v) are subject to and conditioned upon the

2019

Option Agreements with the optionees and the employment agreements with the optionees.

The above actions were unanimously approved by the disinterested members of the Board of Directors. The above actions were intended to eliminate the Company’s potential liability associated with the net cash exercise provision of the Liability Options, and to allow the stockholders of the Company the opportunity to vote on the Amended Plan, which includes shares issuable upon exercise of the

2019

Options. On

May 16, 2019,

the stockholders approved the Amended Plan and thereby approved the issuance of the

2019

Options.

Accounting Treatment

Awards offered under a plan that are subject to shareholder approval are

not

considered granted under GAAP until the approval is obtained, unless such approval is essentially a formality (or perfunctory). For example, if management and board members control sufficient votes to approve the plan, the vote

may

be considered perfunctory. As management and the Company’s Board of Directors did

not

control enough votes to approve the

2019

Options, the

2019

Options were

not

deemed granted under Accounting Standards Codification ("ASC")

718.

Cancellation of an award that is

not

accompanied by the concurrent grant are accounted for as a repurchase for

consideration. Accordingly, any previously unrecognized compensation cost is recognized at the cancellation date. On

January 13, 2019,

as noted above, upon cancellation of the Liability Options the Company recognized

$1,741,919

of unrecognized compensation cost related to the

2018

Liability Options. Additionally, the fair value of the stock-based compensation liability of

$3,151,944

was reclassified to additional-paid in capital on the cancellation date. Shareholder approval was obtained on

May

16,

2019,

which was determined to be the grant date for the

2019

Options, and the Company remeasured and recorded the

2019

Options as a new grant under ASC

718

during the quarter ended

June 30, 2019.

The Company recorded

$4,959,277

in the

second

quarter of

2019

for the

2019

Options granted to the executives.

Note 14 - Subsequent Event	3 Months Ended
Note 14 - Subsequent Event	Mar. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 14: SUBSEQUENT EVENT On April 9, 2020, the Company granted the following stock options (the “2020 Performance Options”) to executives of the Company: (i) to the Chairman of the Board, President and Chief Executive Officer, an option to purchase 1,500,000 shares of Company common stock, 195,000 of which were granted under the Company’s 2010 Plan and 1,305,000 of which were granted under the Company’s 2020 Plan; and (ii) to the Chief Financial Officer, General Counsel and Secretary, an option to purchase 590,000 shares of Company common stock, 195,000 of which were granted under the 2010 Plan and 395,000 of which were granted under the 2020 Plan. The 2020 Performance Options have an exercise price equal to fair market value of the Company’s common stock on the date of grant which was $1.48 per share. The 2020 Performance Options vest quarterly over two years; however, vesting shall accelerate with respect to 50% of any unvested options granted under the 2020 Plan upon U.S. Federal Drug Administration ("FDA") approval of certain therapies. The 2020 Performance Options are subject to the option agreements and employment agreements with the executives. Notwithstanding the foregoing, options granted under the 2020 Plan are not exercisable unless and until the Company’s stockholders approve the 2020 Plan and they automatically expire and terminate if stockholder approval is not obtained within one year of grant. The above actions were unanimously approved by the Compensation Committee of the Board of Directors.

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation: The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 -Q and Rule 10 - 01 of Regulation S- X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10 -K of the Company for the year ended December 31, 2019. The year-end condensed balance sheet presented was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2020, are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense: Research and development ("R&D") costs are generally expensed as incurred. R&D expenses include, for example, manufacturing expenses for our drugs under development, expenses associated with clinical trials and associated salaries and benefits. R&D expenses also include an estimated allocation of the CEO's salary and related benefits including non-cash stock-based compensation expense based on time devoted to R&D.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements: On January 1, 2020, the Company adopted Accounting Standard Update ("ASU") No. 2018 - 13, Fair Value Measurement (Topic 820 ): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement , to improve the effectiveness of disclosures. The amendments remove, modify, and add certain disclosure requirements in Topic 820, “Fair Value Measurement.” The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The adoption had no impact on the Company's condensed consolidated financial statements.

Note 5 - Prepaid Expenses (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

	As of March 31,		As of December 31,
	2020		2019
Prepaid research and development	$	712,387	$	507,733
Prepaid insurance		280,098		222,476
Professional services		278,298		108,850
Financial exchange fees		32,250		-
Retainer and security deposits		14,218		14,218
Prepaid rent		17,952		4,275
Other		1,917		4,792
Total prepaid expenses	$	1,337,120	$	862,344

Note 7 - Payroll Liabilities (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	As of March 31,		As of December 31,
	2020		2019
Accrued bonuses	$	203,779	$	646,064
Accrued vacation		179,533		170,820
Accrued payroll		83,071		82,536
Total payroll liabilities	$	466,383	$	899,420

Note 9 - Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended March 31,
	2020			2019
Numerator
Net loss attributable to common shareholders	$	(2,947,420	)	$	(4,073,307	)
Denominator
Weighted average common shares outstanding used to compute net loss per share, basic and diluted		9,130,984			6,565,514
Net loss per share of common stock, basic and diluted:	$	(0.32	)	$	(0.62	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended March 31,
	2020		2019
Options to purchase common stock		4,308,383		783,383
Series B convertible preferred stock		190,617		458,994
Warrants to purchase common stock		1,070,028		3,369,468
		5,569,028		4,611,845

Note 13 - Stock Based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

January 1,	Number of shares
2012		2,502
2013		2,871
2014		4,128
2015		5,463
2016		7,257
2017		12,623
2018		106,076
2019		233,862
2020		365,239
Total additional shares		740,021

Share-based Payment Arrangement, Option, Activity [Table Text Block]

	Number of Underlying Shares		Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2020		4,308,383	$	3.44				-
Granted		-		-				-
Forfeited		-		-				-
Expired		-		-				-
Outstanding as of March 31, 2020		4,308,383		3.44		8.80	$	-
Exercisable as of March 31, 2020		3,832,000		3.58		8.80	$	-
Vested and expected to vest		4,308,383	$	3.44		8.80	$	-

Liability Options [Member]

Notes Tables

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	January 13,
	2019
Risk free interest rate		2.53	%
Expected term (in years)		4.50-5.00
Stock price	$	1.36
Dividend yield		-	%
Expected volatility		121.0-123.0	%

Share-based Payment Arrangement, Option [Member]

Notes Tables

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended March 31,
	2020		2019
General and administrative	$	483,000	$	224,676
Research and development		204,752		51,157
Total stock compensation expense	$	687,752	$	275,833

	Period Ended March 31, 2019

General and administrative	$	1,074,183
Research and development		667,736
Total stock compensation expense	$	1,741,919

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended
Note 2 - Going Concern (Details Textual) - USD ($)	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Net Income (Loss) Attributable to Parent, Total	$ (2,947,420)	$ (4,073,307)
Net Cash Provided by (Used in) Operating Activities, Total	(3,229,995)	(2,148,956)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	9,351,141	$ 19,568,247	$ 12,581,136
Working Capital	$ 10,800,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Note 4 - Restricted Cash (Details Textual) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Restricted Cash and Cash Equivalents, Total	$ 110,000	$ 110,000	$ 110,000

Note 5 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Prepaid research and development	$ 712,387	$ 507,733
Prepaid insurance	280,098	222,476
Professional services	278,298	108,850
Financial exchange fees	32,250
Retainer and security deposits	14,218	14,218
Prepaid rent	17,952	4,275
Other	1,917	4,792
Total prepaid expenses	$ 1,337,120	$ 862,344

Note 6 - Research and Development Tax Rebate Receivable (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	May 23, 2017
Research and Development Expense, Total	$ 938,620	$ 1,451,236
Research and Development Tax Rebate Receivable	734,340		$ 739,656
Atossa Genetics AUS Pty Ltd [Member]
Research and Development Cash Rebate per Dollar				$ 0.435
Research and Development Expense, Total	$ 133,400	$ 34,700

Note 7 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Accrued bonuses	$ 203,779	$ 646,064
Accrued vacation	179,533	170,820
Accrued payroll	83,071	82,536
Total payroll liabilities	$ 466,383	$ 899,420

Note 8 - Stockholders' Equity (Details Textual) - USD ($)			1 Months Ended	3 Months Ended
	May 08, 2020	Feb. 07, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Number of Shares Authorized to Issue (in shares)				185,000,000
Common Stock, Shares Authorized (in shares)				175,000,000		175,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.18		$ 0.18
Preferred Stock, Shares Authorized (in shares)				10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total (in shares)				671		671
Proceeds from Warrant Exercises			$ 11,300,000	$ 0	$ 11,336,710
Class of Warrant or Right, Exercised During Period (in shares)					2,800,000
Stock Issued During Period, Shares, Warrant Exercised (in shares)					2,800,000
Conversion of Series B Convertible Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)				0	1,677
Conversion of Stock, Shares Issued (in shares)					476,431
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)			284		284
The 2018 Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)				1,070,028
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 4.05
At The Market Offering [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.18
Stock to be Issued, Maximum Value		$ 5,000,000
At The Market Offering [Member] \| Oppenheimer & Co. Inc. [Member]
Stock Issuance Costs, Commission Fee Percent		3.00%
At The Market Offering [Member] \| Oppenheimer & Co. Inc. [Member] \| Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	68,098
Proceeds from Issuance of Common Stock	$ 150,253
Series A Junior Participating Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				750,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001
Preferred Stock, Shares Issued, Total (in shares)				0
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				4,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				25,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001
Sale of Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Issued, Total (in shares)				0

Note 9 - Net Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net loss attributable to common shareholders	$ (2,947,420)	$ (4,073,307)
Weighted average common shares outstanding used to compute net loss per share, basic and diluted (in shares)	9,130,984	6,565,514
Net loss per share of common stock, basic and diluted: (in dollars per share)	$ (0.32)	$ (0.62)

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

+ Details

Note 9 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Number of potential common shares excluded (in shares)	5,569,028	4,611,845
Share-based Payment Arrangement, Option [Member]
Number of potential common shares excluded (in shares)	4,308,383	783,383
Series B Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)	190,617	458,994
Warrant [Member]
Number of potential common shares excluded (in shares)	1,070,028	3,369,468

Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accrued Income Taxes, Total	$ 0	$ 0

Note 11 - Concentration of Credit Risk (Details Textual) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Cash, Uninsured Amount	$ 8,967,650	$ 12,316,429

Note 12 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating Lease, Expense	$ 13,300	$ 12,900
Operating Lease, Weighted Average Remaining Lease Term (Month)	270 days
Operating Lease, Weighted Average Discount Rate, Percent	12.00%
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year	$ 29,500
Lessee, Operating Lease, Liability, to be Paid, Year Two	12,400
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	4,500	12,900
Operating Lease, Payments	$ 14,700	$ 14,600

Note 13 - Stock Based Compensation (Details Textual) - USD ($)							3 Months Ended
	May 16, 2019	Jan. 13, 2019	Jun. 27, 2018	May 09, 2018	Apr. 12, 2018	May 18, 2016	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Sep. 28, 2010
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)
Share-based Payment Arrangement, Expense							$ 687,752		$ 275,833
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)
Adjustments to Additional Paid in Capital, Transfer of Stock-based Compensation Liability Upon Option Cancellation		$ 3,151,944							$ 3,151,944
The 2010 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	3,600,000
Share-based Payment Arrangement, Option [Member] \| The 2010 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)										5,556
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)				125,000	500,000	11,111
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)							0		0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)							0		0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)							676,669
Share-based Payment Arrangement, Expense							$ 687,752		$ 275,833
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares)							476,383
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount							$ 953,046
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)							215 days
Liability Options [Member]
Share-based Payment Arrangement, Expense		$ 1,741,919							$ 1,741,919
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)			$ 1
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)			2019 years
Liability Options [Member] \| Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			2,300,000
Liability Options [Member] \| Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			700,000
The 2019 Options [Member[
Share-based Payment Arrangement, Expense								$ 4,959,277
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 1.36
The 2019 Options [Member[ \| Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		2,300,000
The 2019 Options [Member[ \| Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		800,000

Note 13 - Stock Based Compensation - Additional Shares Authorized (Details) - shares	3 Months Ended	12 Months Ended								99 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2020
The 2010 Stock Option and Incentive Plan [Member]
Total additional shares (in shares)	365,239	233,862	106,076	12,623	7,257	5,463	4,128	2,871	2,502	740,021

Note 13 - Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)		3 Months Ended
	Jan. 13, 2019	Mar. 31, 2020	Mar. 31, 2019
Stock compensation expense		$ 687,752	$ 275,833
General and Administrative Expense [Member]
Stock compensation expense		483,000	224,676
Research and Development Expense [Member]
Stock compensation expense		$ 204,752	51,157
Liability Options [Member]
Stock compensation expense	$ 1,741,919		1,741,919
Liability Options [Member] \| General and Administrative Expense [Member]
Stock compensation expense			1,074,183
Liability Options [Member] \| Research and Development Expense [Member]
Stock compensation expense			$ 667,736

Note 13 - Stock Based Compensation - Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2020 USD ($) $ / shares shares
Granted, shares (in shares) \| shares
Granted, weighted average exercise price per share (in dollars per share) \| $ / shares
Forfeited, shares (in shares) \| shares
Forfeited, weighted average exercise price per share (in dollars per share) \| $ / shares
Expired, shares (in shares) \| shares
Expired, weighted average exercise price per share (in dollars per share) \| $ / shares
The 2010 Stock Option and Incentive Plan [Member]
Outstanding, shares (in shares) \| shares	4,308,383
Outstanding, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 3.44
Outstanding, shares (in shares) \| shares	4,308,383
Outstanding, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 3.44
Outstanding, weighted average contractual life remaining in years (Year)	8 years 292 days
Outstanding, aggreate instrinsic value \| $
Exercisable, shares (in shares) \| shares	3,832,000
Exercisable, Weighted average exercise price per share (in dollars per share) \| $ / shares	$ 3.58
Exercisable, weighted average contractual life remaining in years (Year)	8 years 292 days
Exercisable, aggreate instrinsic value \| $
Vested and expected to vest, shares (in shares) \| shares	4,308,383
Vested and expected to vest, Weighted average exercise price per share (in dollars per share) \| $ / shares	$ 3.44
Vested and expected to vest, weighted average contractual life remaining in years (Year)	8 years 292 days
Vested and expected to vest, aggreate instrinsic value \| $

Note 13 - Stock Based Compensation - Valuation Assumptions (Details) - Liability Options [Member]	Jan. 13, 2020 $ / shares
Risk free interest rate	2.53%
Stock price (in dollars per share)	$ 1.36
Dividend yield
Minimum [Member]
Expected term (in years) (Year)	4 years 182 days
Expected volatility	121.00%
Maximum [Member]
Expected term (in years) (Year)	5 years
Expected volatility	123.00%

Note 14 - Subsequent Event (Details Textual) - $ / shares		3 Months Ended
	Apr. 09, 2020	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)
The 2010 Stock Option and Incentive Plan [Member] \| Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		0	0
Subsequent Event [Member] \| The 2010 Stock Option and Incentive Plan and the 2020 Performance Options Plan [Member] \| Chairman of the Board, President and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	1,500,000
Subsequent Event [Member] \| The 2010 Stock Option and Incentive Plan and the 2020 Performance Options Plan [Member] \| Chief Financial Officer, General Counsel and Secretary [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	590,000
Subsequent Event [Member] \| The 2010 Stock Option and Incentive Plan [Member] \| Chairman of the Board, President and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	195,000
Subsequent Event [Member] \| The 2010 Stock Option and Incentive Plan [Member] \| Chief Financial Officer, General Counsel and Secretary [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	195,000
Subsequent Event [Member] \| The 2020 Performance Options Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 1.48
Subsequent Event [Member] \| The 2020 Performance Options Plan [Member] \| Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	2 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Unvested Percentage for Vesting to Accelerate Under Certain Approvals	50.00%
Subsequent Event [Member] \| The 2020 Performance Options Plan [Member] \| Chairman of the Board, President and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	1,305,000
Subsequent Event [Member] \| The 2020 Performance Options Plan [Member] \| Chief Financial Officer, General Counsel and Secretary [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	395,000